EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Freeline presented early clinical data on its Fabry disease gene therapy. Participants experienced a three- to four-fold increase in plasma αGLA levels. Statement  

> Alderley Park opened a 150,000-square-foot building to house tech startups. The site will enable startups working on drug discovery technologies to base themselves near to biopharma companies. Release  

> AurorA-TT, Rottapharm Biotech and Italfarmaco teamed up to create a biotech investment firm. The company, AurorA Science, will make investments of up to €5 million ($5.5 million) to support preclinical and early clinical development. Statement

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

> Inotrem added €5 million to its series B round. The money, coupled to a new €13 million credit line, will support a phase 2b trial in septic shock patients. Release 

> A phase 2 trial of Oculis’ diabetic macular edema drug met its efficacy endpoints. Statement 

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.

The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19.